Advertisement
Corrigendum
Open Access | 
10.1172/JCI189439
CRISPR/Cas13d targeting suppresses repeat-associated non-AUG translation of C9orf72 hexanucleotide repeat RNA
Honghe Liu, Xiao-Feng Zhao, Yu-Ning Lu, Lindsey R. Hayes, and Jiou Wang
Find articles by Liu, H. in: JCI | PubMed | Google Scholar
Find articles by Zhao, X. in: JCI | PubMed | Google Scholar
Find articles by Lu, Y. in: JCI | PubMed | Google Scholar
Find articles by Hayes, L. in: JCI | PubMed | Google Scholar
Find articles by Wang, J. in: JCI | PubMed | Google Scholar
Published December 16, 2024 - More info
J Clin Invest. 2024;134(24):e189439. https://doi.org/10.1172/JCI189439.
© 2024 Liu et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Related article:
Abstract
A hexanucleotide GGGGCC repeat expansion in the non-coding region of the C9orf72 gene is the most common genetic mutation identified in patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The resulting repeat RNA and dipeptide repeat proteins from non-conventional repeat translation have been recognized as important markers associated with the diseases. CRISPR/Cas13d, a powerful RNA-targeting tool, has faced challenges in effectively targeting RNA with stable secondary structures. Here we report that CRISPR/Cas13d can be optimized to specifically target GGGGCC repeat RNA. Our results demonstrate that the CRISPR/Cas13d system can be harnessed to significantly diminish the translation of poly-dipeptides originating from the GGGGCC repeat RNA. This efficacy has been validated in various cell types, including induced pluripotent stem cells and differentiated motor neurons originating from C9orf72-ALS patients, as well as in C9orf72 repeat transgenic mice. These findings demonstrate the application of CRISPR/Cas13d in targeting RNA with intricate higher-order structures and suggest a potential therapeutic approach for ALS and FTD.
Authors
Honghe Liu, Xiao-Feng Zhao, Yu-Ning Lu, Lindsey R. Hayes, Jiou Wang
Original citation J Clin Invest. 2024;134(21):e179016. https://doi.org/10.1172/JCI179016
Citation for this corrigendum: J Clin Invest. 2024;134(24):e189439. https://doi.org/10.1172/JCI189439
During the preparation of this manuscript, an involved patent was mistakenly omitted from the conflict-of-interest statement. The correct statement is below. The HTML and PDF versions of the manuscript have been updated.
HL and JW are listed as inventors on a patent application (application number: 63313150) filed by Johns Hopkins University on technologies related to this manuscript.
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)